Preclinical Innovation Program (PIP) (R01)

archived

This Funding Opportunity Announcement (FOA), the Preclinical Innovation Program (PIP), issued by NIAID, encourages Research Project Grant (R01) applications in non-vaccine biomedical prevention (nBP) research. The PIP is intended to support high risk/innovative research and development efforts designed to establish and maintain a sustainable pipeline of nBP candidates, drug delivery systems (DDS) and supporting technologies for the prevention of HIV acquisition/transmission. The PIP will support novel and under-explored approaches to strengthen and maintain an innovative pipeline of nBP strategies including microbicides, pre-exposure prophylaxis (PrEP), and Multipurpose Prevention Technologies (MPT). To accomplish this, the PIP will also support a range of nBP DDS including, but not limited to, pericoital and sustained delivery of single and combination candidates and strategies using gels, films, intravaginal rings (IVR), oral, implant and/or injection delivery methods. The PIP is a replacement program for the Microbicide Innovation Program (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-10-011.html) and investigators are urged to read the current FOA closely to identify critical differences between this and previous programs.

High